Patents Assigned to Aduro Biotech, Inc.
-
Publication number: 20170333552Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and preferably Rp,Rp stereoisomers thereof.Type: ApplicationFiled: July 31, 2017Publication date: November 23, 2017Applicants: ADURO BIOTECH, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Thomas W. Dubensky, JR., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura H. Glickman, Russell E. Vance
-
Patent number: 9808516Abstract: Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to immunogenic fusion proteins and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins.Type: GrantFiled: April 12, 2016Date of Patent: November 7, 2017Assignees: Aduro Biotech, Inc., The Johns Hopkins UniversityInventors: Dirk G. Brockstedt, Charles G. Drake, Marcella Fasso, Peter M. Lauer, William G. Hanson, Meredith Lai Ling Leong, Christopher Steven Rae
-
Patent number: 9775891Abstract: The present invention relates to methods of inducing a T-cell response against a EGFRvIII in a subject. These method comprise administering to a subject a composition which expresses at least one immunogenic polypeptide, the amino acid sequence of which comprise a plurality of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3), and/or administering the polypeptide itself.Type: GrantFiled: November 25, 2015Date of Patent: October 3, 2017Assignees: ADURO BIOTECH, INC., PROVIDENCE HEALTH & SERVICES—OREGONInventors: Peter M. Lauer, Keith Bahjat
-
Patent number: 9770467Abstract: The present invention provides a combination therapy which relies on a small molecule immune stimulator—cyclic-di-nucleotide (CDN)—that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes) formulated with allogeneic human tumor cell lines engineered to secrete high amounts of GM-CSF. This combination therapy can provide an ideal synergy of multiple tumor associated antigens, DC recruitment and proliferation, coupled with a potent DC activation stimulus.Type: GrantFiled: June 7, 2013Date of Patent: September 26, 2017Assignees: ADURO BIOTECH, INC., THE JOHNS HOPKINS UNIVERSITYInventors: Thomas W. Dubensky, Jr., Meredith Lai Ling Leong, Drew M. Pardoll, Young Jun Kim
-
Patent number: 9764013Abstract: The invention provides a bacterium containing a polynucleotide comprising a nucleic acid encoding a heterologous antigen, as well as fusion protein partners. Also provided are vectors for mediating site-specific recombination and vectors comprising removable antibiotic resistance genes.Type: GrantFiled: November 12, 2013Date of Patent: September 19, 2017Assignee: ADURO BIOTECH, INC.Inventors: Thomas W. Dubensky, Jr., Justin Skoble, Peter M. Lauer, David N. Cook
-
Patent number: 9724408Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and preferably Rp,Rp stereoisomers thereof.Type: GrantFiled: May 18, 2014Date of Patent: August 8, 2017Assignees: ADURO BIOTECH, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Thomas W. Dubensky, Jr., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura H. Glickman, Russell E. Vance
-
Patent number: 9695212Abstract: It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.Type: GrantFiled: December 13, 2013Date of Patent: July 4, 2017Assignee: Aduro Biotech, Inc.Inventors: Thomas W. Dubensky, Jr., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura Hix Glickman
-
Patent number: 9663557Abstract: The present invention provides nucleic acids, expression systems, and vaccine strains which provide efficient expression and secretion of antigens of interest into the cytosol of host cells, and elicit effective CD4 and CD8 T cell responses by functionally linking Listerial or other bacterial signal peptides/secretion chaperones as N-terminal fusion partners in translational reading frame with selected recombinant encoded protein antigens. These N-terminal fusion partners are deleted (either by actual deletion, by mutation, or by a combination of these approaches) for any PEST sequences native to the sequence, and/or for certain hydrophobic residues.Type: GrantFiled: December 27, 2013Date of Patent: May 30, 2017Assignee: ADURO BIOTECH, INC.Inventors: Peter M. Lauer, William G. Hanson, Justin Skoble, Meredith Lai Ling Leong, Marcella Fasso, Dirk Brockstedt, Thomas W. Dubensky, Jr.
-
Patent number: 9549944Abstract: The present invention provides cyclic-di-nucleotide (CDN) compounds that inhibit signaling at a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides which inhibit STING-dependent TBK1 activation and the resulting production of type I interferon.Type: GrantFiled: May 19, 2014Date of Patent: January 24, 2017Assignee: ADURO BIOTECH, INC.Inventors: Thomas W. Dubensky, Jr., David B. Kanne
-
Patent number: 9511129Abstract: The present invention provides facultatively attenuated bacterial species and methods of preparation and use thereof. The term “facultatively attenuated” as used herein refers to a bacterium which comprises a set of defined recombinant modifications which have substantially no effect on the ability of the bacterium to grow by multiplication when the bacterium is outside of its host organism, but which result in deletion of one or more genes essential for multiplication of the bacterium when the bacterium is introduced into its host organism, for example within host cells of a vaccinate recipient. These recombinant modifications take advantage of regulatory sequences which preferentially induce expression of genes within the mammalian host.Type: GrantFiled: November 6, 2013Date of Patent: December 6, 2016Assignee: ADURO BIOTECH, INC.Inventors: William G. Hanson, Justin Skoble, Peter M. Lauer
-
Patent number: 9198960Abstract: Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.Type: GrantFiled: January 5, 2015Date of Patent: December 1, 2015Assignee: Aduro Biotech, Inc.Inventors: Thomas W. Dubensky, Jr., Dirk G. Brockstedt, Meredith Lai Ling Leong, Keith S. Bahjat
-
Patent number: 9161974Abstract: Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.Type: GrantFiled: May 23, 2011Date of Patent: October 20, 2015Assignee: ADURO BIOTECH, INC.Inventors: Thomas W. Dubensky, Dirk G. Brockstedt, Meredith Leong, Keith S. Bahjat
-
Publication number: 20150056224Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and preferably Rp,Rp stereosiomers thereof.Type: ApplicationFiled: May 18, 2014Publication date: February 26, 2015Applicants: ADURO BIOTECH, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Thomas W. Dubensky, JR., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura H. Glickman, Russell E. Vance
-
Publication number: 20140341976Abstract: The present invention provides cyclic-di-nucleotide (CDN) compounds that inhibit signaling at a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides which inhibit STING-dependent TBK1 activation and the resulting production of type I interferon.Type: ApplicationFiled: May 19, 2014Publication date: November 20, 2014Applicant: ADURO BIOTECH, INC.Inventors: Thomas W. Dubensky, JR., David B. Kanne
-
Publication number: 20140205653Abstract: It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.Type: ApplicationFiled: December 13, 2013Publication date: July 24, 2014Applicant: Aduro Biotech, Inc.Inventors: Thomas W. Dubensky, JR., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura Hix Glickman
-
Publication number: 20140186387Abstract: The present invention provides nucleic acids, expression systems, and vaccine strains which provide efficient expression and secretion of antigens of interest into the cytosol of host cells, and elicit effective CD4 and CD8 T cell responses by functionally linking Listerial or other bacterial signal peptides/secretion chaperones as N-terminal fusion partners in translational reading frame with selected recombinant encoded protein antigens. These N-terminal fusion partners are deleted (either by actual deletion, by mutation, or by a combination of these approaches) for any PEST sequences native to the sequence, and/or for certain hydrophobic residues.Type: ApplicationFiled: December 27, 2013Publication date: July 3, 2014Applicant: ADURO BIOTECH, INC.Inventors: Peter M. Lauer, William G. Hanson, Justin Skoble, Meredith Lai Ling Leong, Marcella Fasso, Dirk Brockstedt, Thomas W. Dubensky, JR.
-
Patent number: 8287883Abstract: The present invention provides Listeria that are attenuated for entry into non-phagocytic cells as well as a variety of methods of inducing immune responses involving administering compositions comprising the attenuated Listeria. Some of the attenuated Listeria are mutant Listeria that comprise at least one mutation in a gene encoding an invasin, such as an internalin. Some of the attenuated Listeria are further attenuated for cell-to-cell spread. Pharmaceutical compositions and vaccines useful in the methods of the invention are further provided. Methods of making and improving vaccines are also provided.Type: GrantFiled: March 29, 2010Date of Patent: October 16, 2012Assignee: Aduro Biotech, Inc.Inventors: Thomas W. Dubensky, Jr., Dirk G. Brockstedt, David N. Cook